Bio News

Belgium’s Amadcell Therapeutics acquired two CAR T therapies from Lakefront Biotherapeutics for non-Hodgkin lymphoma and small cell lung cancer.
Amadcell will pay Lakefront an upfront €8 million (about 10.7 billion won) and could pay up to an additional $230 million (about 308.2 billion won) in the future.
Amadcell will also take over three undisclosed projects in early preclinical development and has appointed Willemijn Kremer as its new CEO.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%